Regarding fibroblast growth factor receptor-2 (FGFR2), an emerging IHC marker, which is a major transducer of signals between tumor and its microenvironment (TME), mediating interactions between TME and hormone receptor-dependent pathways [28,29,30,31,32,33,34,35], Braun M. et al. [36] demonstrated the application of an ML algorithm for evaluating this marker’s expression in breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.